1 month Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?The Motley Fool
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
X